Oncologists are increasingly using technology to precisely diagnose the biological mechanisms driving a patient’s tumor, to predict which therapies are likely to be most effective in block-ing them, and to monitor the patient’s response in real time. Learn how these technologies are transforming the practice of oncology into a science.
Vik evaluates and pursues investments at the intersection of technology and life sciences, including in personalized and precision healthcare. Prior to joining Foresite Capital, Vik was the chief scientific officer of GRAIL, a life sciences company working to detect cancer early when it can be cured, and remains on its Scientific Advisory Board. He is also the co-founder and former chief scientific officer of Verily (formerly Google Life Sciences) and served as chair of its Scientific Advisory Board. A former academic principal investigator, Vik retains appointments as associate professor (consulting) at the Stanford School of Medicine, and as an affiliate scientist of the Lawrence Berkeley National Laboratory and the University of California, Berkeley, for which he serves on the advisory board of the College of Chemistry. He is an advisor to the Department of Defense through the Defense Science Board’s Task Force on Biology. Vik’s research interests lie at the interface of the physical sciences, engineering, and the life sciences. He and his collaborators have developed nanotechnology probes for the early detection and molecular imaging of disease, spectroscopic tools for imaging objects on the nanoscale, microfabricated and miniaturized analytical and imaging systems for point-of-care testing, methods and devices that dramatically enhance the sensitivity and specificity of MRI, and new tools for clinical bioinformatics and integrative systems biology. Aspects of this work have been commercialized through several startups. At GRAIL, Vik led laboratory and data science teams at the forefront of industrial cancer genomics and diagnostics development.
Matt cofounder Notable Labs in 2014. Currently his responsibilities include leading the overall vision and strategy, partnerships, recruiting, and any other company-related matters. Previously he was as a portfolio manager and trader at Clarium Capital, a global macro hedge fund. Matt started his career on a foreign exchange and interest rate sales and trading desk at Bank of America Merrill Lynch. Matt received his BA magna cum laude in Applied Economics and Management from Cornell University where he captained the cross country team and ran the 1,500 and 5,000 meter distance for the Big Red track team.
Designing Clinical Trials For Patients Not Drugs
Randomized controlled clinical trials have changed little since their inception. Bayesian statistical methods, technologies that stratify patients, and initial success in breast cancer should make adaptive trials more common. This talk will cover how adaptive trials benefit patients by making it more likely they receive an effective drug and benefit drug companies by reducing approval time and cost.